Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Iptacopan Clear all

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Orange, California + 5 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 4
States / cities: Atlanta, Georgia • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Generalized Myasthenia Gravis
Interventions: Iptacopan, Matching Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fullerton, California • Sacramento, California + 10 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 11 more

Conditions: Age-Related Macular Degeneration
Interventions: Iptacopan (LNP023), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 22
States / cities: Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more

Conditions: Primary Immunoglobulin A Nephropathy (IgAN)
Interventions: iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Madera, California • Aurora, Colorado • Gainesville, Florida + 2 more

Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions: Iptacopan, Placebo, Rituximab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Mesa, Arizona • Rochester, Minnesota

Conditions: Primary IgA Nephropathy
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 16
States / cities: Glendale, Arizona • San Diego, California • San Dimas, California + 13 more

Conditions: Immunoglobulin A Nephropathy
Interventions: No intervention, Other treatment, Iptacopan, Atrasentan; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2036
U.S. locations: 5
States / cities: Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: LNP023, Eculizumab, Ravulizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Orange, California • Augusta, Georgia + 2 more

Conditions: Hepatic Impairment
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: IgA Nephropathy
Interventions: Placebo, LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 22
States / cities: Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Miami Lakes, Florida + 6 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: PNH-relevant therapies; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: C3G
Interventions: Placebo, iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more

Conditions: Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lupus Nephritis
Interventions: Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • San Bernardino, California • Sylmar, California + 13 more

Conditions: Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more

Conditions: IC-MPGN
Interventions: Placebo, iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 18 more

Search by objective public record fields.

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Iptacopan in Patients With ANCA Associated Vasculitis

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Home Reported Outcomes in PNH

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN